Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lenora Lehwald

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Neurology and Neuroscience Reports|June 17, 2018
Neurologic Consequences of Preterm BirthMargie A Ream, Lenora Lehwald
Journal of Child Neurology|December 28, 2020
Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case SeriesEva Wibbeler, Raymond Wang, Emily de Los Reyes, et al.
Pediatric Neurology|July 21, 2020
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US ClinicsEmily de Los Reyes, Lenora Lehwald, Erika F Augustine, et al.
SAGE Open Medicine|November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndromeDragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Pediatric Neurology|March 25, 2017
Management Strategies for CLN2 DiseaseRuth E Williams, Heather R Adams, Martin Blohm, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Neurology and Neuroscience Reports|June 17, 2018
Neurologic Consequences of Preterm BirthMargie A Ream, Lenora Lehwald
Journal of Child Neurology|December 28, 2020
Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case SeriesEva Wibbeler, Raymond Wang, Emily de Los Reyes, et al.
Pediatric Neurology|July 21, 2020
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US ClinicsEmily de Los Reyes, Lenora Lehwald, Erika F Augustine, et al.
SAGE Open Medicine|November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndromeDragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Pediatric Neurology|March 25, 2017
Management Strategies for CLN2 DiseaseRuth E Williams, Heather R Adams, Martin Blohm, et al.
Pageof 1